✦ LIBER ✦

Postoperative chemo–endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor–positive stage II breast cancer

✍ Scribed by Keizo Sugimachi; Yoshihiko Maehara; Kohei Akazawa; Yasuo Nomura; Kazuyuki Eida; Michio Ogawa; Eiji Konaga; Noriaki Tanaka; Tetsuya Toge; Kiyohiko Dohi; Shoichihi Noda; Masazumi Maeda; Yasumasa Monden

Book ID: 110233241
Publisher: Springer US
Year: 1999
Tongue: English
Weight: 113 KB
Volume: 56
Category: Article
ISSN: 0167-6806
DOI: 10.1023/a:1006221425652

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN15 PHARMACOECONOMIC ANALYSIS OF EXEME

PCN15 PHARMACOECONOMIC ANALYSIS OF EXEMESTANE VERSUS TAMOXIFEN AS ADJUVANT THERAPY FOR PATIENTS WITH EARLY-STAGE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER

✍ JM Gil; A Lluch; P González; A Del Castillo; F Canorea; C Rubio-Terrés 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Benefit and projected cost-effectiveness

Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor–positive breast cancer

✍ Bruce E. Hillner 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 1 views

## Abstract ## BACKGROUND Women who have estrogen receptor (ER)‐positive disease with postmenopausal onset and who receive tamoxifen as standard adjuvant treatment constitute the largest subgroup of patients with breast cancer. Recent data from the ATAC (‘Arimidex, Tamoxifen Alone or in Combinatio